Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A phase 3 trial has found that a Regeneron melanoma drug was unable to outperform Keytruda. The outcome of the trial has reportedly been met with disappointment. Meanwhile, Regeneron has also been involved in a separate deal to develop a new class of drugs, although it is unclear how this may relate to the melanoma treatment.